Display options
Cite
Shimizu J, Sasaki T, Yamanaka A, et al. The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production. Sci Rep. 2021;11(1):23713doi: 10.1038/s41598-021-03273-0.
Shimizu, J., Sasaki, T., Yamanaka, A., Ichihara, Y., Koketsu, R., Samune, Y., Cruz, P., Sato, K., Tanga, N., Yoshimura, Y., Murakami, A., Yamada, M., Itoi, K., Nakayama, E. E., Miyazaki, K., & Shioda, T. (2021). The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production. Scientific reports, 11(1), 23713. https://doi.org/10.1038/s41598-021-03273-0
Shimizu, Jun, et al. "The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production." Scientific reports vol. 11,1 (2021): 23713. doi: https://doi.org/10.1038/s41598-021-03273-0
Shimizu J, Sasaki T, Yamanaka A, Ichihara Y, Koketsu R, Samune Y, Cruz P, Sato K, Tanga N, Yoshimura Y, Murakami A, Yamada M, Itoi K, Nakayama EE, Miyazaki K, Shioda T. The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production. Sci Rep. 2021 Dec 09;11(1):23713. doi: 10.1038/s41598-021-03273-0. PMID: 34887501; PMCID: PMC8660863.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2021 Dec 09;11(1):23713. doi: 10.1038/s41598-021-03273-0.

The potential of COVID-19 patients' sera to cause antibody-dependent enhancement of infection and IL-6 production.

Scientific reports

Jun Shimizu, Tadahiro Sasaki, Atsushi Yamanaka, Yoko Ichihara, Ritsuko Koketsu, Yoshihiro Samune, Pedro Cruz, Kei Sato, Naomi Tanga, Yuka Yoshimura, Ami Murakami, Misuzu Yamada, Kiyoe Itoi, Emi E Nakayama, Kazuo Miyazaki, Tatsuo Shioda

Affiliations

  1. MiCAN Technologies Inc., KKVP 1-36, Goryo-ohara, Nishikyo-Ku, Kyoto, 615-8245, Japan.
  2. Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University, 3-1, Yamada-oka, Suita, Osaka, 565-0871, Japan.
  3. Faculty of Tropical Medicine, Mahidol-Osaka Center for Infectious Diseases, Mahidol University, Bangkok, Thailand.
  4. MiCAN Technologies Inc., KKVP 1-36, Goryo-ohara, Nishikyo-Ku, Kyoto, 615-8245, Japan. [email protected].
  5. Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University, 3-1, Yamada-oka, Suita, Osaka, 565-0871, Japan. [email protected].
  6. Faculty of Tropical Medicine, Mahidol-Osaka Center for Infectious Diseases, Mahidol University, Bangkok, Thailand. [email protected].

PMID: 34887501 PMCID: PMC8660863 DOI: 10.1038/s41598-021-03273-0

Abstract

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many vaccine trials have been initiated. An important goal of vaccination is the development of neutralizing antibody (Ab) against SARS-CoV-2. However, the possible induction of antibody-dependent enhancement (ADE) of infection, which is known for other coronaviruses and dengue virus infections, is a particular concern in vaccine development. Here, we demonstrated that human iPS cell-derived, immortalized, and ACE2- and TMPRSS2-expressing myeloid cell lines are useful as host cells for SARS-CoV-2 infection. The established cell lines were cloned and screened based on their function in terms of susceptibility to SARS-CoV-2-infection or IL-6 productivity. Using the resulting K-ML2 (AT) clone 35 for SARS-CoV-2-infection or its subclone 35-40 for IL-6 productivity, it was possible to evaluate the potential of sera from severe COVID-19 patients to cause ADE and to stimulate IL-6 production upon infection with SARS-CoV-2.

© 2021. The Author(s).

References

  1. J Clin Epidemiol. 2018 Mar;95:137-139 - PubMed
  2. Cell. 2021 Aug 5;184(16):4203-4219.e32 - PubMed
  3. J Virol. 2001 Mar;75(5):2324-30 - PubMed
  4. Nat Microbiol. 2020 Oct;5(10):1185-1191 - PubMed
  5. Trends Microbiol. 2018 Mar;26(3):186-190 - PubMed
  6. EClinicalMedicine. 2021 Feb;32:100734 - PubMed
  7. Sci Rep. 2021 Jun 14;11(1):12448 - PubMed
  8. Lancet. 2021 Feb 6;397(10273):452-455 - PubMed
  9. J Gen Virol. 2018 Sep;99(9):1239-1247 - PubMed
  10. Rev Med Virol. 2020 Nov;30(6):1-9 - PubMed
  11. Vaccines (Basel). 2021 Jan 15;9(1): - PubMed
  12. Hum Immunol. 2013 Oct;74(10):1400-8 - PubMed
  13. Lancet Respir Med. 2020 Jul;8(7):687-695 - PubMed
  14. Immunol Rev. 2015 Nov;268(1):340-64 - PubMed
  15. Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7 - PubMed
  16. J Virol Methods. 2010 Feb;163(2):205-9 - PubMed
  17. Cell. 2000 Mar 3;100(5):575-85 - PubMed
  18. N Engl J Med. 2020 Oct 22;383(17):1695 - PubMed
  19. J Leukoc Biol. 2020 Jul;108(1):17-41 - PubMed
  20. Front Immunol. 2020 Jun 16;11:1446 - PubMed
  21. J Immunol. 1990 Apr 15;144(8):3183-6 - PubMed
  22. Emerg Infect Dis. 2021 Apr;27(4): - PubMed
  23. Nature. 2020 Aug;584(7821):353-363 - PubMed
  24. Clin Infect Dis. 2020 Nov 5;71(8):1937-1942 - PubMed
  25. Science. 2020 May 1;368(6490):473-474 - PubMed
  26. Cell. 2020 May 28;181(5):1016-1035.e19 - PubMed
  27. Cell. 2020 Oct 1;183(1):143-157.e13 - PubMed
  28. Gene Ther. 2013 May;20(5):504-13 - PubMed
  29. N Engl J Med. 2020 Oct 22;383(17):1695-1696 - PubMed
  30. Vaccine. 2009 Jan 22;27(4):505-12 - PubMed
  31. Virol J. 2014 May 06;11:82 - PubMed
  32. JCI Insight. 2020 Sep 3;5(17): - PubMed
  33. Heliyon. 2020 Nov 03;6(11):e05407 - PubMed
  34. N Engl J Med. 2020 Oct 22;383(17):1694-1695 - PubMed
  35. Euro Surveill. 2021 Jan;26(1): - PubMed
  36. Lancet. 2020 Feb 15;395(10223):497-506 - PubMed
  37. Nat Rev Immunol. 2020 Oct;20(10):633-643 - PubMed
  38. Cell. 2021 Jun 24;184(13):3452-3466.e18 - PubMed
  39. PLoS One. 2016 Apr 06;11(4):e0152384 - PubMed
  40. Clin Exp Immunol. 2015 Jul;181(1):126-32 - PubMed
  41. Viral Immunol. 2003;16(1):69-86 - PubMed
  42. Nature. 2021 Feb;590(7847):635-641 - PubMed
  43. Inflamm Regen. 2020 Oct 1;40:37 - PubMed
  44. Lancet Respir Med. 2020 Dec;8(12):1233-1244 - PubMed
  45. N Engl J Med. 2015 Sep 24;373(13):1195-206 - PubMed
  46. Cell. 2020 Apr 16;181(2):271-280.e8 - PubMed
  47. Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3 - PubMed
  48. Science. 2020 Aug 7;369(6504):718-724 - PubMed
  49. Cell Rep. 2021 Feb 2;34(5):108699 - PubMed
  50. Cytokine. 2020 Dec;136:155256 - PubMed
  51. J Virol. 2020 Feb 14;94(5): - PubMed
  52. Lancet Microbe. 2020 May;1(1):e14-e23 - PubMed
  53. Lancet. 1988 Apr 9;1(8589):790-4 - PubMed
  54. Nat Commun. 2020 Nov 13;11(1):5752 - PubMed

Publication Types

Grant support